Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash & Equivalents (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Cash & Equivalents for 6 consecutive years, with $52.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 87.85% to $52.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.3 million through Dec 2025, down 87.85% year-over-year, with the annual reading at $52.3 million for FY2025, 87.85% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $52.3 million at Janux Therapeutics, up from $48.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $430.6 million in Q4 2024, with the low at $14.7 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $98.8 million, with a median of $52.3 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents surged 2142.15% in 2024, then plummeted 87.85% in 2025.
  • Over 5 years, Cash & Equivalents stood at $35.6 million in 2021, then skyrocketed by 44.53% to $51.4 million in 2022, then crashed by 62.66% to $19.2 million in 2023, then soared by 2142.15% to $430.6 million in 2024, then tumbled by 87.85% to $52.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $52.3 million, $48.4 million, and $52.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.